| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | QL-XI-92 | GDSC1000 | pan-cancer | AAC | 0.042 | 0.2 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | -0.21 | 0.2 |
| mRNA | doxorubicin:navitoclax (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.044 | 0.2 |
| mRNA | GSK1070916 | GDSC1000 | pan-cancer | AAC | -0.043 | 0.2 |
| mRNA | GSK1059615 | CTRPv2 | pan-cancer | AAC | -0.061 | 0.2 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | -0.046 | 0.2 |
| mRNA | ZM-447439 | GDSC1000 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | tigecycline | CTRPv2 | pan-cancer | AAC | -0.063 | 0.2 |
| mRNA | regorafenib | CTRPv2 | pan-cancer | AAC | 0.049 | 0.2 |
| mRNA | BAY 61-3606 | GDSC1000 | pan-cancer | AAC | 0.046 | 0.2 |